- Home
- AKTX vs GOVX Comparison
AKTX vs GOVX Comparison
Compare AKTX & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- GOVX
- Stock Information
- Founded
- AKTX N/A
- GOVX 2001
- Country
- AKTX United States
- GOVX United States
- Employees
- AKTX N/A
- GOVX N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- AKTX Health Care
- GOVX Health Care
- Exchange
- AKTX Nasdaq
- GOVX Nasdaq
- Market Cap
- AKTX 29.5M
- GOVX 23.8M
- IPO Year
- AKTX N/A
- GOVX N/A
- Fundamental
- Price
- AKTX $0.99
- GOVX $2.26
- Analyst Decision
- AKTX
- GOVX Strong Buy
- Analyst Count
- AKTX 0
- GOVX 5
- Target Price
- AKTX N/A
- GOVX $14.20
- AVG Volume (30 Days)
- AKTX 91.8K
- GOVX 721.5K
- Earning Date
- AKTX 02-15-2025
- GOVX 11-12-2024
- Dividend Yield
- AKTX N/A
- GOVX N/A
- EPS Growth
- AKTX N/A
- GOVX N/A
- EPS
- AKTX N/A
- GOVX N/A
- Revenue
- AKTX N/A
- GOVX $3,090,161.00
- Revenue This Year
- AKTX N/A
- GOVX N/A
- Revenue Next Year
- AKTX N/A
- GOVX $159.12
- P/E Ratio
- AKTX N/A
- GOVX N/A
- Revenue Growth
- AKTX N/A
- GOVX N/A
- 52 Week Low
- AKTX $0.90
- GOVX $1.09
- 52 Week High
- AKTX $4.40
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- AKTX 31.38
- GOVX 44.80
- Support Level
- AKTX $0.95
- GOVX $2.17
- Resistance Level
- AKTX $1.13
- GOVX $2.50
- Average True Range (ATR)
- AKTX 0.15
- GOVX 0.17
- MACD
- AKTX 0.02
- GOVX -0.04
- Stochastic Oscillator
- AKTX 15.15
- GOVX 18.33
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.